---
title: "Ensysce Biosciences completes Cy Biopharma acquisition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295106106.md"
description: "Ensysce Biosciences completed the acquisition of Cy Biopharma, securing clinical-stage candidate CY200 for complex regional pain syndrome. The deal includes USD 17.1 million in cash and a concurrent private placement targeting USD 21.5 million gross, with an additional USD 38.6 million follow-on tranche tied to clinical milestones. Funds will support Phase 2 development and registrational preparation through 2028."
datetime: "2026-08-06T12:12:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295106106.md)
  - [en](https://longbridge.com/en/news/295106106.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295106106.md)
---

# Ensysce Biosciences completes Cy Biopharma acquisition

-   Ensysce completed the acquisition of privately held Cy Biopharma, adding clinical-stage neuroplastogenic candidate CY200 for complex regional pain syndrome. \* CY200 holds U.S. FDA Orphan Drug Designation for CRPS, with funding aimed at Phase 2 topline data and registrational preparation. \* Transaction brought in USD 17.1 million of Cy Biopharma cash from a pre-acquisition convertible note financing. \* Concurrent private placement of Series C non-voting convertible preferred stock targets USD 21.5 million gross at initial close. \* Financing includes up to a USD 38.6 million follow-on tranche tied to a clinical trial milestone, expected to fund development into 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ENSC.US](https://longbridge.com/en/quote/ENSC.US.md)
- [ENSCW.US](https://longbridge.com/en/quote/ENSCW.US.md)

## Related News & Research

- [Ensysce Biosciences posts investor presentation spotlighting trypsin-controlled opioid platforms, pain pipeline](https://longbridge.com/en/news/295107304.md)
- [Ensysce Biosciences Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295841617.md)
- [Rocket Sharing says Mexedia completes purchase of 51% stake in Stantup Service](https://longbridge.com/en/news/295563109.md)
- [Nielsen's $2 billion DoubleVerify acquisition is a big play for CMOs](https://longbridge.com/en/news/295662101.md)
- [Pfizer just raised its 2026 guidance -- but the boost leans heavily on a drug running out the patent clock](https://longbridge.com/en/news/295581210.md)